Abstract
As of March 2021, coronavirus disease 2019 (COVID-19) had caused more than 123 million infections and almost 3 million deaths worldwide. Dramatic advances have been made in vaccine development and nonpharmaceutical interventions to stop the spread of infection. However, treatments to stop disease progression are limited. A wide variety of “repurposed” drugs evaluated for treatment of COVID-19 have had little or no benefit. More recently, intravenous monoclonal antibody (mAb) combinations have been authorized by the US Food and Drug Administration for emergency use for outpatients with mild to moderate COVID-19 including some active against emerging severe acute respiratory syndrome coronavirus 2 variants of concern. Easier to administer therapeutics including intramuscular and subcutaneous mAbs and oral antivirals are in clinical trials. Reliable, safe, effective COVID-19 treatment for early infection in the outpatient setting is of urgent and critical importance. Availability of such treatment should lead to reduced progression of COVID-19.
Keywords: COVID-19; antivirals; monoclonal antibodies; outpatients.
【저자키워드】 COVID-19, antivirals, monoclonal antibodies, outpatients, 【초록키워드】 Treatment, coronavirus disease, Coronavirus disease 2019, Vaccine development, coronavirus, Antiviral, Therapeutics, monoclonal antibody, Infection, variants of concern, clinical trials, Nonpharmaceutical interventions, drug, progression, monoclonal antibodies, Moderate COVID-19, Spread, Disease progression, death, Mild, outpatients, respiratory, Critical, monoclonal, intramuscular, mAb, Emergency use, food, Outpatient, Combination, nonpharmaceutical intervention, early infection, Safe, intravenous, lead, mild to moderate, Mild to moderate COVID-19, US Food and Drug Administration, acute respiratory syndrome, treatment of COVID-19, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, effective, benefit, caused, evaluated, reduced, variety, active against, administer, 【제목키워드】 coronavirus 2, Outpatient,